1Staudt A, B6hm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G-3 subclass incardiac dysfunction among patients with dilated cardiomyopathy[J]. Circulation, 2002,106 (19) .. 2448-2453.
2Nagatomo Y, Baba A, Ito H, et al. Specific immunoadsorption therapy using a tryptophan column in patients with refractory heart failure due to dilated cardiomyopathy[J]. J Clin Apher, 2011,26(1) .. 1-8.
3Dandel M, Wallukat G, Potapov E, et al. Role of 0n- adrenoceptor autoantibodies in the pathogenesis of dilated cardiomyopathy[J]. Immunobiology, 2012,217 (5) : 511-520.
4Jahns R, Boivin V, Lohse MJ. ~l-Adrenergic receptor function, autoimmunity, and pathogenesis of dilated cardiomyopathy[J]. Trends Cardiovasc Med, 2006,16 ( 1 ) .. 20- 24.
5Xia Y, Kellems RE. Receptor-activating autoantibodies and disease: preeclampsia and beyond l-J]. Expert Rev Clin Immunol, 2011,7(5) : 659-674.
6Yoshikawa T, Baba A, Nagatomo Y. Autoimmune mechanisms underlying dilated cardiomyopathy[J]. Circ J, 2009,73 (4) : 602-607.
7Sdnchez LA, Guerrero-Beltrdn CE, Cordero-Reyes AM, et al. Use of stem cells in heart failure treatment: where we stand and where we are going [J ]. Methodist Debakey Cardiovasc J, 2013,9 (4) : 195-200.
8De Rosa S, Seeger FH, Honold J, et al. Procedural safety and predictors of acute outcome of intracoronary administration of progenitor cells in 775 consecutive procedures performed for acute myocardial infarction or chronic heart failure[J]. Circ Cardiovasc Interv, 2013,6 (1)2 44-51.
9Messori A, Fadda V, Maratea D, et al. Intracoronary infusion of bone-marrow derived mononuclear cells in acute myocardial infarction: Are outcomes influenced by thenumber of infused cells? [J]. Heart Lung Circ, 2013,22 (9) : 786-787.
10Seth S, Bhargava B, Narang R, et al. The ABCD (autologous bone marrow cells in dilated cardiomyopathy) trial a long-term follow-up studyFJ]. J Am Coil Cardiol, 2010,55(15) : 1643-1644.
